Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Serum HMGB1 levels are independently associated with glucose clamp-derived measures of insulin resistance in women with PCOS.

Journal of endocrinological investigation·2023
Same author

Trimester-specific reference intervals for thyroid function parameters in pregnant Caucasian women using Roche platforms: a prospective study.

Journal of endocrinological investigation·2023
Same author

The Italian Society of Andrology and Sexual Medicine (SIAMS), along with ten other Italian Scientific Societies, guidelines on the diagnosis and management of erectile dysfunction.

Journal of endocrinological investigation·2023
Same author

The physiological sonographic features of the ovary in healthy subjects: a joint systematic review and meta-analysis by the Italian Society of Gynecology and Obstetrics (SIGO) and the Italian Society of Endocrinology (SIE).

Journal of endocrinological investigation·2022
Same author

Prevalence of Vertebral Fractures and Non-fracture Deformities in Healthy Adult Men: The Importance of Morphologic Criteria.

Calcified tissue international·2022
Same author

Sympathetic activation in heart failure<sup></sup>.

European heart journal supplements : journal of the European Society of Cardiology·2022
Same journal

Expression of IL-35 in the Prophase of Liver Failure and its Immune Regulatory Interaction with Glucocorticoids.

Endocrine, metabolic & immune disorders drug targets·2026
Same journal

Celastrol Attenuates Fgf23 Expression in Osteoblasts by Inhibiting STAT3 Activation.

Endocrine, metabolic & immune disorders drug targets·2026
Same journal

Mendelian Randomization Analysis of the Inflammatory Factor CXCL5 and Type 2 Diabetes Mellitus.

Endocrine, metabolic & immune disorders drug targets·2026
Same journal

Clinical Exome Sequencing Study in a Cohort of Growth Hormone-Secreting Pituitary Adenomas.

Endocrine, metabolic & immune disorders drug targets·2026
Same journal

A Review of the Mechanisms, Biological Basis, and Active Ingredients of Traditional Chinese Medicine Formulations in Regulating Organ Function to Alleviate Osteoporosis.

Endocrine, metabolic & immune disorders drug targets·2026
Same journal

Potential of IL-33 as a Novel Myokine in Sarcopenia-Osteoporosis Communication: Insights from Mendelian Randomization.

Endocrine, metabolic & immune disorders drug targets·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Managing erectile dysfunction in heart failure.

V A Giagulli1, P Moghetti, J M Kaufman

  • 1O.U. Metabolic Disease and Endocrinology, P.O. Conversano, Via De Amicis, 3070014 Conversano-Ba, Italy. vitogiagulli@alice.it

Endocrine, Metabolic & Immune Disorders Drug Targets
|February 2, 2013
PubMed
Summary
This summary is machine-generated.

Erectile dysfunction (ED) is a key indicator of cardiovascular risk in men with heart failure (HF). Early diagnosis and treatment of ED, especially with PDE5 inhibitors, can improve outcomes for HF patients.

Related Experiment Videos

Last Updated: May 14, 2026

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility
04:22

Treatment Model for Young Patients with Psychogenic Erectile Dysfunction and Resultant Infertility

Published on: May 30, 2025

Area of Science:

  • Cardiology
  • Urology
  • Internal Medicine

Background:

  • Erectile dysfunction (ED) is a significant clinical concern in men with heart failure (HF).
  • ED serves as a sentinel marker for cardiovascular events, particularly in men under 65 or with type 2 diabetes mellitus.
  • Sexual activity can pose risks for patients with advanced heart failure (NYHA III-IV class).

Purpose of the Study:

  • To review current evidence on managing ED in men with HF.
  • To highlight the interplay between ED, HF, and cardiovascular risk.
  • To discuss therapeutic strategies for ED in the context of HF management.

Main Methods:

  • Literature review of recent studies on ED and HF.
  • Analysis of drug effects on ED in heart failure patients.
  • Evaluation of PDE5 inhibitors for ED treatment in HF.

Main Results:

  • ED is an important consideration influencing treatment approaches in heart failure patients.
  • Certain HF medications may exacerbate or cause ED.
  • Phosphodiesterase type 5 (PDE5) inhibitors show promise for treating ED in NYHA class I-II HF patients, with favorable effects on cardiopulmonary parameters and quality of life.

Conclusions:

  • ED requires early diagnosis and appropriate management in men with heart failure.
  • PDE5 inhibitors appear to be a safe and effective option for ED in early-stage HF patients.
  • Integrated management of ED and HF is crucial for improving patient outcomes.